share_log

424B5: Prospectus

424B5: Prospectus

424B5：募資說明書
美股SEC公告 ·  07/24 17:10

Moomoo AI 已提取核心訊息

60 Degrees Pharmaceuticals, trading under the symbol SXTP on The Nasdaq Capital Market, has filed a prospectus supplement on July 24, 2024, to increase the maximum aggregate gross sales price of shares offered under its Sales Agreement with WallachBeth Capital LLC to $1,890,705. This move, referred to as the ATM Offering Size Increase, amends previous registrations of common stock worth $1,253,603 and $1,774,640. As of the filing date, 60 Degrees Pharmaceuticals has sold 4,964,249 shares for a gross sales price of $0.2811 per share. The company's outstanding common stock held by non-affiliates is valued at approximately $5,672,117, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, which limits the sale of securities in a public primary offering to no more than one-third of the public float in a 12-month period, provided the public float is below $75 million. The prospectus supplement also highlights significant investment risks, as detailed in the Risk Factors sections of the accompanying documents and filings with the SEC.
60 Degrees Pharmaceuticals, trading under the symbol SXTP on The Nasdaq Capital Market, has filed a prospectus supplement on July 24, 2024, to increase the maximum aggregate gross sales price of shares offered under its Sales Agreement with WallachBeth Capital LLC to $1,890,705. This move, referred to as the ATM Offering Size Increase, amends previous registrations of common stock worth $1,253,603 and $1,774,640. As of the filing date, 60 Degrees Pharmaceuticals has sold 4,964,249 shares for a gross sales price of $0.2811 per share. The company's outstanding common stock held by non-affiliates is valued at approximately $5,672,117, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, which limits the sale of securities in a public primary offering to no more than one-third of the public float in a 12-month period, provided the public float is below $75 million. The prospectus supplement also highlights significant investment risks, as detailed in the Risk Factors sections of the accompanying documents and filings with the SEC.
藥品60度，標的爲SXTP，在納斯達克資本市場上交易，於2024年7月24日提交補充招股說明書，將其與WallachBeth Capital LLC的銷售協議中提供的股票的最大總銷售價格提高至1,890,705美金。此舉被稱爲ATm Offering Size Increase，修訂了之前的普通股註冊價值1,253,603美金和1,774,640美金。截至提交日期，60度藥品已售出4,964,249股，每股0.2811美金。公司的未公開持股由非關聯方持有，截至2024年6月7日的股價爲0.351美金，大約價值5,672,117美金。該公司遵守SEC的S-3表格的I.b.6通用說明，限制在12個月內公開初次發行的證券銷售量不超過公共浮動的三分之一，前提是公共浮動低於7500萬美金。招股說明書還強調了重要的投資風險，詳細說明在伴隨文件和提交給SEC的文件中的風險因素部分。
藥品60度，標的爲SXTP，在納斯達克資本市場上交易，於2024年7月24日提交補充招股說明書，將其與WallachBeth Capital LLC的銷售協議中提供的股票的最大總銷售價格提高至1,890,705美金。此舉被稱爲ATm Offering Size Increase，修訂了之前的普通股註冊價值1,253,603美金和1,774,640美金。截至提交日期，60度藥品已售出4,964,249股，每股0.2811美金。公司的未公開持股由非關聯方持有，截至2024年6月7日的股價爲0.351美金，大約價值5,672,117美金。該公司遵守SEC的S-3表格的I.b.6通用說明，限制在12個月內公開初次發行的證券銷售量不超過公共浮動的三分之一，前提是公共浮動低於7500萬美金。招股說明書還強調了重要的投資風險，詳細說明在伴隨文件和提交給SEC的文件中的風險因素部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間